Hepcortespenlisimut-L

Drug Profile

Hepcortespenlisimut-L

Alternative Names: Hepko-V5; V-5; V-5 Immunitor

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator Immunitor
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • No development reported Hepatitis B; Hepatitis C; Tuberculosis

Most Recent Events

  • 13 Apr 2017 Hepcortespenlisimut-L licensed to Key Capital Group
  • 13 Apr 2017 Efficacy and pharmacodynamics data from a phase II trial in Hepatocellular carcinoma released by Immunitor
  • 17 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top